<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:06:06Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5591020" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5591020</identifier><datestamp>2017-12-16</datestamp><setSpec>ajhg</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Am J Hum Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Am. J. Hum. Genet</journal-id>
      <journal-title-group>
        <journal-title>American Journal of Human Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0002-9297</issn>
      <issn pub-type="epub">1537-6605</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5591020</article-id>
      <article-id pub-id-type="pmcid">PMC5591020</article-id>
      <article-id pub-id-type="pmc-uid">5591020</article-id>
      <article-id pub-id-type="pmid">28886343</article-id>
      <article-id pub-id-type="publisher-id">S0002-9297(17)30327-0</article-id>
      <article-id pub-id-type="doi">10.1016/j.ajhg.2017.08.005</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Dominant Mutations in <italic>GRM1</italic> Cause Spinocerebellar Ataxia Type 44</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Watson</surname>
            <given-names>Lauren M.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bamber</surname>
            <given-names>Elizabeth</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schnekenberg</surname>
            <given-names>Ricardo Parolin</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Williams</surname>
            <given-names>Jonathan</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bettencourt</surname>
            <given-names>ConceiÃ§Ã£o</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">4</xref>
          <xref rid="aff5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lickiss</surname>
            <given-names>Jennifer</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fawcett</surname>
            <given-names>Katherine</given-names>
          </name>
          <xref rid="aff7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Clokie</surname>
            <given-names>Samuel</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wallis</surname>
            <given-names>Yvonne</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Clouston</surname>
            <given-names>Penny</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sims</surname>
            <given-names>David</given-names>
          </name>
          <xref rid="aff7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houlden</surname>
            <given-names>Henry</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Becker</surname>
            <given-names>Esther B.E.</given-names>
          </name>
          <email>esther.becker@dpag.ox.ac.uk</email>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="fn1" ref-type="fn">9</xref>
          <xref rid="cor1" ref-type="corresp">â</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>NÃ©meth</surname>
            <given-names>Andrea H.</given-names>
          </name>
          <email>andrea.nemeth@ndcn.ox.ac.uk</email>
          <xref rid="aff2" ref-type="aff">2</xref>
          <xref rid="aff8" ref-type="aff">8</xref>
          <xref rid="fn1" ref-type="fn">9</xref>
          <xref rid="cor2" ref-type="corresp">ââ</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, UK</aff>
      <aff id="aff2"><label>2</label>Nuffield Department of Clinical Neurosciences, University of Oxford, 6th Floor West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK</aff>
      <aff id="aff3"><label>3</label>Oxford Medical Genetics Laboratories, Churchill Hospital, Oxford OX3 7LE, UK</aff>
      <aff id="aff4"><label>4</label>Department of Molecular Neuroscience, Institute of Neurology, University College London, London WC1N 3BG, UK</aff>
      <aff id="aff5"><label>5</label>Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London WC1N 3BG, UK</aff>
      <aff id="aff6"><label>6</label>West Midlands Regional Genetics Laboratory, Birmingham Womenâs and Childrenâs NHS Foundation Trust, Birmingham B15 2TG, UK</aff>
      <aff id="aff7"><label>7</label>MRC Computational Genomics Analysis and Training Programme, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK</aff>
      <aff id="aff8"><label>8</label>Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford OX3 7HE, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>â</label>Corresponding author <email>esther.becker@dpag.ox.ac.uk</email></corresp>
        <corresp id="cor2"><label>ââ</label>Corresponding author <email>andrea.nemeth@ndcn.ox.ac.uk</email></corresp>
        <fn id="fn1">
          <label>9</label>
          <p id="ntpara0010">These authors contributed equally to this work</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>07</day>
        <month>9</month>
        <year>2017</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <day>07</day>
        <month>9</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>07</day>
        <month>9</month>
        <year>2017</year>
      </pub-date>
      <volume>101</volume>
      <issue>3</issue>
      <fpage>451</fpage>
      <lpage>458</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>6</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>7</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2017 The Author(s)</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <p>The metabotropic glutamate receptor 1 (mGluR1) is abundantly expressed in the mammalian central nervous system, where it regulates intracellular calcium homeostasis in response to excitatory signaling. Here, we describe heterozygous dominant mutations in <italic>GRM1</italic>, which encodes mGluR1, that are associated with distinct disease phenotypes: gain-of-function missense mutations, linked in two different families to adult-onset cerebellar ataxia, and a <italic>de novo</italic> truncation mutation resulting in a dominant-negative effect that is associated with juvenile-onset ataxia and intellectual disability. Crucially, the gain-of-function mutations could be pharmacologically modulated <italic>inÂ vitro</italic> using an existing FDA-approved drug, Nitazoxanide, suggesting a possible avenue for treatment, which is currently unavailable for ataxias.</p>
      </abstract>
      <kwd-group id="kwrds0010">
        <title>Keywords</title>
        <kwd>mGluR1</kwd>
        <kwd>glutamate</kwd>
        <kwd>calcium</kwd>
        <kwd>cerebellum</kwd>
        <kwd>ataxia</kwd>
        <kwd>atrophy</kwd>
        <kwd>intellectual disability</kwd>
        <kwd>Purkinje cells</kwd>
        <kwd>Homer</kwd>
        <kwd>nitazoxanide</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <p id="misc0010">Published: September 7, 2017</p>
    </notes>
  </front>
  <body>
    <sec id="sec1">
      <title>Main Text</title>
      <p id="p0010">Glutamate is the most abundant excitatory neurotransmitter in the mammalian brain.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Postsynaptic glutamate signaling is mediated by two classes of receptors: ionotropic glutamate receptors (iGluRs), which mediate rapid synaptic transmission; and metabotropic glutamate receptors (mGluRs), which are coupled to G proteins and produce a more complex postsynaptic response consisting of both internal calcium release and a slow excitatory postsynaptic potential. mGluR1, encoded by <italic>GRM1</italic> (MIM: <ext-link ext-link-type="omim" xlink:href="604473" id="intref0010">604473</ext-link>), is one of the most abundant mGluRs in the mammalian central nervous system and is present at particularly high levels in Purkinje cells, the primary neurons of the cerebellar cortex. Multiple lines of evidence have implicated mGluR1 as a central player in diseases involving glutamatergic dysfunction and abnormal synaptic plasticity.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Nevertheless, disease-causing mutations within <italic>GRM1</italic> itself appear remarkably rare.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> The only <italic>GRM1</italic> mutations identified to date have been found either to cause an autosomal-recessive spinocerebellar ataxia (SCAR13 [MIM: <ext-link ext-link-type="omim" xlink:href="614831" id="intref0015">614831</ext-link>]) in a small Roma cohort with a known founder effect<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> or to associate with autosomal-recessive intellectual disability in a single consanguineous Iranian family.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></p>
      <p id="p0015">Here, we report heterozygous dominant mutations in <italic>GRM1</italic> associated with two distinct phenotypes. Missense mutations in <italic>GRM1</italic> were identified in two different families with an adult-onset degenerative disorder primarily causing cerebellar ataxia with some cortical involvement causing spasticity: c.2375A&gt;G (p.Tyr792Cys) in family 1 and c.785A&gt;G (p.Tyr262Cys) in family 2 (<xref rid="fig1" ref-type="fig">Figures 1</xref>A and 1B). The clinical presentation in families 1 and 2 is of a slowly progressive cerebellar ataxia with onset between 20 and 50 years (see <xref rid="mmc1" ref-type="supplementary-material">Supplemental Note</xref>). There was no evidence of cognitive impairment, but in family 1, individual III:1 has evidence of corticospinal tract involvement with a narrow stiff gait and brisk reflexes. Brain MRI inÂ members of both families revealed cerebellar atrophy, with mild flattening of the pons in family 1. Genetic testing for spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7, and 17 (MIM: <ext-link ext-link-type="omim" xlink:href="164400" id="intref0020">164400</ext-link>, <ext-link ext-link-type="omim" xlink:href="183090" id="intref0025">183090</ext-link>, <ext-link ext-link-type="omim" xlink:href="109150" id="intref0030">109150</ext-link>, <ext-link ext-link-type="omim" xlink:href="183086" id="intref0035">183086</ext-link>, <ext-link ext-link-type="omim" xlink:href="164500" id="intref0040">164500</ext-link>, andÂ 607136) did not detect any mutations. We also identified a heterozygous base pair duplication in <italic>GRM1</italic> in another individual (c.3165dup [p.Gly1056Argfs<sup>â</sup>49]). In family 3 the parents are unaffected, but the child has intellectual disability and cerebellar ataxia without apparent cerebellar atrophy, and normal brain imaging (<xref rid="fig1" ref-type="fig">FigureÂ 1</xref>A).<fig id="fig1"><label>FigureÂ 1</label><caption><p>Dominant Mutations in <italic>GRM1</italic> Result in a Cerebellar Phenotype</p><p>(A) MRI brain imaging of case subjects. Top left: family 1, affected son (II:1); top right: family 1, affected granddaughter (III:1), both showing cerebellar atrophy. Bottom left: family 2, affected brother (II:1) showing cerebellar atrophy; bottom right: family 3, affected daughter (II:1), showing normal imaging. The cerebellum is indicated in each case by an arrow.</p><p>(B) Pedigrees of affected families. Squares denote male family members, circles female family members, and black symbols affected family members. Probands are indicated in each case by an arrow. The following individuals were sequenced: family 1 I:2, II:1, and III:1; family 2 II:1, II:2, and III:1; family 3 I:1, I:2, and II:1. Asterisks (<sup>â</sup>) indicate the presence of the mutation.</p><p>(C) Schematic representation of the positions of the dominant mutations within mGluR1. At the N terminus, the amino-terminal domain (ATD) is followed by the cysteine-rich domain (CRD), seven transmembrane domains (TMD), and the intracellular C-terminalÂ domain (CTD). Cysteine residues, which function in dimerization, are indicated by S. <italic>GRM1</italic> mutations are indicated by black stars. The p.Tyr262Cys variant is located in the extracellular ligand-binding region, p.Tyr792Cys within transmembrane helix 6, and p.Gly1056Argfs<sup>â</sup>49 in the C-terminal domain of the receptor. FigureÂ adapted from Willard and Koochekpour.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></p></caption><graphic xlink:href="gr1"/></fig></p>
      <p id="p0020">Consent for participation in the study was obtained according to the Declaration of Helsinki (WMA, 1997) and approved by the Central Oxford Research Ethics Committee and the Research and Development Department of the Oxford Radcliffe Hospitals NHS Trust (approval number C03.052), Oxford. Work at University College London Hospitals was conducted under UCLH Project ID Number: 08/0512/26. All participating individuals or their parents provided written consent for the study.</p>
      <p id="p0025">Variants of interest in <italic>GRM1</italic> were identified by means of whole-exome (families 1 and 2) or targeted (family 3) sequencing, with results verified by Sanger sequencing. In the case of family 1, Covaris shearing of DNA was followed by library preparation using the Agilent SureSelect Exome V5 probe kit and SureSelectXT target enrichment chemistry. The prepared libraries were sequenced by 2Ã 100-bp paired end sequencing on a HiSeq2500 in rapid run mode. A minimum of 98.37% of the on-target regions were covered to a depth of at least 20Ã. The exome data were processed using an in-house bioinformatic pipeline as previously described.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></p>
      <p id="p0030">For family 2, whole-exome sequencing (WES) was performed in the three family members. The TruSeq Exome Enrichment (62 Mb) or the Nextera Rapid Capture Exome (37 Mb) Enrichment kits (Illumina) were used according to the manufacturer instructions. Libraries were sequenced using an Illumina HiSeq2500 using a 100-bp paired-end reads protocol. In the proband, a minimum of 94.66% of the on-target regions were covered to a depth of at least 10Ã. Sequence alignment to the human reference genome (UCSC hg19) and variants call and annotation were performed using an in-house pipeline as described elsewhere.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The raw list of single-nucleotide variants (SNVs) and indels was then filtered. Only exonic and donor/acceptor splicing variants were considered. Priority was given to rare variants (&lt;1% in public databases, including 1000 Genomes project, NHLBI Exome Variant Server, Complete Genomics 69, and Exome Aggregation Consortium [ExAC v0.2] with a GERP++ score above 2). Synonymous variants were not considered nor were variants present in our in-house exome database in phenotypes other than ataxia.</p>
      <p id="p0035">For family 3, targeted sequencing of 92 ataxia-associated genes (see <xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>) was performed in the proband using a custom design Haloplex enrichment kit (Agilent Technologies) on the Ilumina MiSeq platform. Data analysis was performed using an in-house pipeline. Identified variants were filtered against in-house lists of known sequencing artifacts and polymorphisms and of variants found in the Exome Variant Server dataset at a minor allele frequency of 1% or greater. Horizontal coverage of the target genes at a read-depth of 30Ã is included in <xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>. The variant was confirmed as having arisen <italic>de novo</italic> by Sanger sequencing of parental DNA, and familial relationships were confirmed using the AmpFLSTR Identifiler Plus PCR amplification kit (ThermoFisher Scientific).</p>
      <p id="p0040">Both the heterozygous c.2375A&gt;G (p.Tyr792Cys) (family 1) and c.785A&gt;G (p.Tyr262Cys) (family 2) missense variants were predicted to be pathogenic by standard bioinformatics pathogenicity programs (<xref rid="tbl1" ref-type="table">Table 1</xref>). The heterozygous c.3165dup (p.Gly1056Argfs<sup>â</sup>49) variant identified in the proband of family 3 occurs in the final <italic>GRM1</italic> exon, and as such is not predicted to be subject to nonsense-mediated decay (NMD) but rather to result in the production of a truncated protein. The presence of protein levels for all three variants was confirmed following transient overexpression in HEK293FT cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>A and 2C), although further confirmation of p.Gly1056Argfs<sup>â</sup>49 mGluR1 levels in primary cells would be necessary to conclusively rule out the possibility of NMD.<fig id="fig2"><label>FigureÂ 2</label><caption><p>Deletion of the C-Terminal Domain of mGluR1 Affects Binding to Homer2b</p><p><italic>GRM1</italic> expression constructs were generated using GRM1-Tango (Addgene plasmid 66387),<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> into which a stop codon was inserted to prevent readthrough into the Tango element. The three dominant mutations were introduced by site-directed mutagenesis, and results were verified by Sanger sequencing. Constructs were transfected into HEK293FT cells (Invitrogen), using Lipofectamine 3000 (Thermo Fisher Scientific). 24Â hr after transfection, cells were subjected to immunostaining using the following primary antibodies: mouse anti-FLAG (1:500; Sigma-Aldrich), rabbit anti-MYC (1:500; Abcam), and goat anti-mGluR1 (1:500; Santa-Cruz). Secondary antibodies: goat anti-mouse Alexa594 or Alexa488, goat anti-rabbit Alexa488, and donkey anti-goat Alexa594 (all 1:1,000; Life Technologies). Nuclei were stained with DAPI.</p><p>(A) Cells transfected with FLAG-tagged mGluR1 only (left) show diffuse localization of wild-type (WT) and mutant mGluR1 (red). Co-transfection with MYC-tagged Homer2b results in clustering of WT mGluR1 and the p.Tyr262Cys and p.Tyr792Cys mutants but not the p.Gly1056Argfs<sup>â</sup>49 deletion mutant. Scale bar: 20Â Î¼m.</p><p>(B) Quantitative analysis of mGluR1-Homer2b clustering. For each biological replicate, 100 cells were counted. Bars show the mean of three biological replicates Â± SEM. <sup>âââ</sup>p &lt; 0.001 (one-way ANOVA, followed by Bonferroniâs multiple comparison test).</p><p>(C) Western blot analysis of mGluR1 and components of its downstream signaling cascade. Protein extracts were prepared from cultured cells 24Â hr after transfection, in ice-cold RIPA buffer (Thermo Fisher) containing 1Ã cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail (Roche), 1Ã PhosSTOP (Roche), and 1Â mM dithiothreitol (DTT), and analyzed by standard SDS-polyacrylamide gel electrophoresis and immunoblotting. Primary antibodies: rabbit anti-mGluR1 (1:200; Alomone Labs), rabbit anti-p44/42 MAPK (Erk1/2) and rabbit anti-phospho-p44/42 MAPK (Erk1/2) (both 1:1,000; Cell Signaling Technologies), and mouse anti-actin (1:1,000; Abcam). HRP-conjugated secondary antibodies: donkey anti-rabbit and sheep anti-mouse (both 1:10,000; GE Healthcare). A decrease in phosphorylation of Extracellular Signal-Related Kinase 1/2 (ERK1/2) was observed in cells transfected with the mGluR1 p.Gly1056Argfs<sup>â</sup>49 mutant, indicating disruption of mGluR1 downstream signaling events.</p></caption><graphic xlink:href="gr2"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Summary of <italic>GRM1</italic> Variants Identified by Sequencing in Affected Families</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>Family 1</bold></th><th><bold>Family 2</bold></th><th><bold>Family 3</bold></th></tr></thead><tbody><tr><td>Genome reference</td><td>GRCh37:g.146720550A&gt;G</td><td>GRCh37:g.146480568A&gt;G</td><td>GRCh37:g.146755512dup</td></tr><tr><td>Transcript</td><td>NM_001278064.1</td><td>NM_001278064.1</td><td>NM_001278064.1</td></tr><tr><td>Nucleotide</td><td>c.2375A&gt;G</td><td>c.785A&gt;G</td><td>c.3165dup</td></tr><tr><td>Protein</td><td>p.Tyr792Cys</td><td>p.Tyr262Cys</td><td>p.Gly1056Argfs<sup>â</sup>49</td></tr><tr><td>PhyloP</td><td>5.05 [-14.1;6.4]</td><td>4.56 [-14.1;6.4]</td><td>not applicable</td></tr><tr><td>Grantham</td><td>194 [0-215]</td><td>194 [0-215]</td><td>not applicable</td></tr><tr><td>PolyPhen</td><td>0.999 (probably damaging)</td><td>0.999 (probably damaging)</td><td>not applicable</td></tr><tr><td>Align GVGD</td><td>C65 (GV:0.00 - GD:193.72)</td><td>C0 (GV:353.86 - GD:0.00)</td><td>not applicable</td></tr><tr><td>SIFT</td><td>score: 0, median: 4.32</td><td>score: 0, median: 4.32</td><td>not applicable</td></tr><tr><td>Mutation Taster</td><td>disease causing (p value: 1)</td><td>disease causing (p value: 1)</td><td>not applicable</td></tr><tr><td>ExAc</td><td>absent</td><td>absent</td><td>absent</td></tr></tbody></table></table-wrap></p>
      <p id="p0045">Publicly available gene and protein expression data (Allen Mouse Brain Atlas and Human Brain Transcriptome Project) show particularly high levels of mGluR1 in the Purkinje cells of the cerebellar cortex, where its signaling is critically important for memory formation, motor learning, and co-ordination.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Activation of mGluR1 in response to glutamatergic signaling at Purkinje cell excitatory synapses triggers a complex pathway involving inositol triphosphate receptor-dependent release of intracellular calcium. The correct function of mGluR1 in these signaling cascades is facilitated by a number of interaction partners, including the scaffold protein Homer2b.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Binding of the intracellular C-terminal domain of group I mGluRs to Homer2b results in recruitment and clustering of both proteins at the plasma membrane<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> and contributes to the organization of efficient signaling domains.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref> To assess the effect of the identified <italic>GRM1</italic> mutations on this clustering, HEK293FT cells were transiently co-transfected with mGluR1 and Homer2b followed by immunostaining. For each <italic>GRM1</italic> mutation, 100 cells co-expressing FLAG-tagged mGluR1 and Homer2b were counted, and the distribution of mGluR1 was classified as either âclusteredâ or âdiffuseâ based on the presence or absence of punctate staining in each cell. Representative images of this clustering are shown in <xref rid="fig2" ref-type="fig">FigureÂ 2</xref>A. For further verification, immunostaining of cells using an anti-FLAG antibody was compared with immunostaining using an antibody against the N terminus of mGluR1 (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S1</xref>). Expression of the truncation mutation (p.Gly1056Argfs<sup>â</sup>49) resulted in complete ablation ofÂ mGluR1-Homer2b clustering (<xref rid="fig2" ref-type="fig">Figures 2</xref>A and 2B). By contrast, the missense mutations (p.Tyr262Cys and p.Tyr792Cys) showed similar clustering patterns to wild-type (WT) mGluR1, indicating that neither of these mutations affects the clustering with Homer2b. Of note, overexpression of p.Gly1056Argfs<sup>â</sup>49 mGluR1 was also associated with decreased levels of phosphorylated ERK1/2, a downstream target of activated mGluR1,<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> when compared to WT-mGluR1 or either of the point mutations (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>C).</p>
      <p id="p0050">To evaluate the effects of each mutation on mGluR1 receptor activity, we employed a luciferase assay based on mGluR1-induced transcriptional activation following arrestin translocation (Tango), as previously described (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>A).<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Consistent with the results of the immunostaining and biochemical experiments, p.Gly1056Argfs<sup>â</sup>49 mGluR1 showed dramatically reduced receptor activity relative to WT (p &lt; 0.01) (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C). Taken together, these results suggest that the truncating mGluR1 mutation causes a dominant-negative effect, resulting in a loss of receptor function and consequent disruption of downstream signaling events.<fig id="fig3"><label>FigureÂ 3</label><caption><p><italic>GRM1</italic> Mutations Affect Receptor Activity and Can Be Pharmacologically Modulated <italic>InÂ Vitro</italic></p><p>(A) Overview of the modified luciferase reporter assay used toÂ assess mGluR1 activity. The GRM1-Tango construct, into which mutations were introduced, consists of a FLAG-tagged GRM1 sequence followed by the Tango element, i.e., a V<sub>2</sub> tail capable of recruiting Î²-arrestin, a cleavage site for the tobacco etch virus (TEV) protease, and a tetracycline-controlled transactivator (tTA). <italic>GRM1</italic> mutations are indicated by black stars. Signaling via mGluR1 results in a conformational change in the V<sub>2</sub> tail and recruitment of Î²-arrestin, followed by TEV protease-mediated cleavage and release of tTA, which translocates to the nucleus and activates transcription of the luciferase reporter gene, resulting in a quantifiable output of mGluR1 activity in the form of luminescence (figure adapted from Kroeze etÂ al.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>).</p><p>(B) Structure of the mGluR1 endogenous ligand, L-glutamate, and the inhibitors used in this study: competitive inhibitor MCPG, inverse agonist BAY36-7620, and the FDA-approved negative allosteric modulator Nitazoxanide.</p><p>(C) Relative activity of mGluR1 mutants. HTLA cells, stably expressing a Î²-arrestin/TEV protease complex and a tTA-dependent luciferase reporter gene, were seeded at 70,000 cells/well onto poly-L-lysine-coated 96-well plates in DMEM without L-glutamine (Life Technologies), containing penicillin, streptomycin, hygromycin B, and puromycin. After 24Â hr, cells were transiently transfected with the four GRM1-Tango constructs (WT, p.Tyr262Cys, p.Tyr792Cys, and p.Gly1056Argfs<sup>â</sup>49) and incubated for a further 24Â hr. Cells were then treated overnight with 500Â Î¼M (<italic>RS</italic>)-MPCG (Tocris), 10Â Î¼M BAY36-7620 (Tocris), or 10Â Î¼M Nitazoxanide (Sigma-Aldrich), diluted in assay buffer (20Â mM HBSS, 1Ã HEPES [pH 7.4], both Life Technologies), before cell lysis in Bright-Glo solution (Promega) and luminescence reading. Data were analyzed statistically in GraphPad Prism using a two-way analysis of variance (ANOVA), followed by Bonferroniâs multiple comparison post hoc test. Significance was defined as p &lt; 0.05 and is shown here relative to mGluR1 wild-type (WT) in the untreated condition and relative to the corresponding untreated sample for all other treatment conditions, unless otherwise indicated. Data shown are mean Â± SEM from one experiment, representative of results recorded in four biological replicates, each consisting of threeÂ technical replicates per construct per condition. <sup>â</sup>p &lt; 0.05, <sup>ââ</sup>p &lt; 0.01, <sup>âââ</sup>p &lt; 0.001, <sup>ââââ</sup>p &lt; 0.0001.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0055">By contrast, both missense mutations resulted in significantly enhanced receptor activity compared to WT (p &lt; 0.0001) (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C), suggesting a gain-of-function mechanism. To determine whether this effect was due toÂ enhanced ligand sensitivity or a result of ligand-independent activation, mGluR1-transfected cells were treated with either a competitive (MCPG) or a non-competitive (BAY36-7620) antagonist of mGluR1. Treatment with either antagonist partially reduced the activity of p.Tyr262Cys and p.Tyr792Cys mGluR1 (p &lt; 0.0001). However, a combination of both antagonists was required toÂ reduce mutant and WT receptor activity to similar levelsÂ (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C), suggesting a role for both ligand-dependent and -independent mechanisms in the enhanced activity resulting from these mutations. These results are in keeping with the molecular genetics results and inÂ silico pathogenicity predictions. Both missense mutations are located near regions responsible for the regulation of mGluR1 activation in response to glutamate signalingâp.Tyr262Cys in the ligand-binding domain and p.Tyr792Cys in helix VI of the transmembrane domain.<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref> Structural analysis of mGluR1 has revealed a putative role of p.Tyr262Cys in stabilization of the open-open conformation; hence, it is possible that substitution at this position results in an increase in receptors in the active conformation.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> The same structural analysis has shown that helix VI undergoes a substantial conformational change during receptor activation, a process that may be disrupted by the p.Tyr792Cys substitution. As further evidence for the importance of this region, the nearby Trp798 residue has been shown to be directly involved in binding of an allosteric regulator of mGluR1 activity.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p>
      <p id="p0060">Mutations that result in excessive mGluR1 signaling have been hypothesized to result in excitotoxicity via a positive-feedback mechanism, in which elevated intracellular calcium potentiates mGluR1-mediated signals.<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> Cerebellar Purkinje cells in particular appear acutely sensitive to these fluctuations in calcium levels, which may explain the link between gain of mGluR1 function and the development of cerebellar ataxia.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Interestingly, mutations in genes encoding proteins in the mGluR1 signaling pathway, that result in activation of this pathway,Â have been linked to ataxia in several cases, including the <italic>Moonwalker</italic> ataxic mouse model<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> and the late-onset, dominantly inherited human diseases SCA1 (MIM: <ext-link ext-link-type="omim" xlink:href="164400" id="intref0045">164400</ext-link>),<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> SCA2 (MIM: <ext-link ext-link-type="omim" xlink:href="183090" id="intref0050">183090</ext-link>),<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> SCA28 (MIM: <ext-link ext-link-type="omim" xlink:href="610246" id="intref0055">610246</ext-link>),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> and SCA41 (MIM: <ext-link ext-link-type="omim" xlink:href="616410" id="intref0060">616410</ext-link>),<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> which share common clinical features with the individuals carrying <italic>GRM1</italic> missense mutations in the present study.</p>
      <p id="p0065">The <italic>de novo</italic> p.Gly1056Argfs<sup>â</sup>49 variant, on the other hand, produces a truncated form of mGluR1 lacking the C-terminal domain. This region of the protein, containing the crucial Homer binding motif, plays an important role in receptor targeting and the regulation of signal transduction.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Hence, it seems likely that deletion of the Homer binding domain would result in a loss of receptor function, and given the requirement for dimerization of the mGluR1 receptor,<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> non-functional monomers likely exert a dominant-negative effect, accounting for the manifestation of disease in the heterozygous state.</p>
      <p id="p0070">The consequences of a loss of mGluR1 function are emphasized by results from knockout models, which show a range of developmental and functional deficits, both in the cerebellum (impaired long-term depression, movement ataxia, abnormal innervations of Purkinje cells, and compensatory mGluR5-mediated excitotoxicity)<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref> and in other brain regions, including impaired long-term potentiation in the hippocampus and disruption of pre-pulse inhibition.<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref> This is further supported by recent reports of altered mGluR1 levels during neurodevelopment, in the hippocampus of a rat model of schizophrenia, highlighting the critical role of glutamate receptors across several brain regions.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> In humans too, mutations resulting in a loss of glutamate signaling are typically associated with a more severe neurodevelopmental phenotype. For example, individuals carrying the likely loss-of-function mutations in <italic>GRM1</italic> reported by Guergueltcheva etÂ al.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> and Davarniya etÂ al.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> or null mutations in the ionotropic glutamate receptor gene <italic>GRID2</italic> (MIM: <ext-link ext-link-type="omim" xlink:href="602368" id="intref0065">602368</ext-link>)<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref> all showed evidence of developmental delay and intellectual deficit in addition to cerebellar ataxia, similar to the individual carrying a <italic>deÂ novo GRM1</italic> nonsense frameshift mutation described here, albeit to a larger extent. Moreover, epilepsy was described in one of the reported families with recessive inheritance<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> and spasticity was described in one individual<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> as well as in a spontaneous recessive <italic>Grm1</italic> mouse mutant.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> Interestingly, spasticity was also observed in one individual (family 1, III:1) reported here. Together, these phenotypes are suggestive of cortical dysfunction and point toward a critical role for mGluR1 in the development and function of additional brain regions beyond the cerebellum.</p>
      <p id="p0075">Pharmacological modulation of mGluR1 activity is attracting increasing attention as a promising therapeutic approach for the treatment of cerebellar ataxia.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Indeed, negative modulators of mGluR1 activity have already been used with some success in the treatment of ataxia symptoms in mouse models.<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib39" ref-type="bibr">39</xref> In an attempt to identify a readily available potential therapeutic compound, we selected Nitazoxanide, an FDA-approved drug, that was identified in a recent <italic>in silico</italic>-<italic>inÂ vivo</italic> repositioning study as a negative allosteric modulator of mGluR1/5<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> and examined its ability to rescue the excessive mGluR1 signaling caused by the p.Tyr262Cys and p.Tyr792Cys missense variants <italic>inÂ vitro</italic>. Treatment with a single 10Â Î¼M dose of Nitazoxanide proved to be a potent inhibitor of both of these mutant forms of mGluR1 in transiently transfected HEK293FT cells, as assessed by the Tango luciferase assay (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C). Given the structural similarity of its active metabolite tizoxanide to the inverse agonist BAY36-7620,<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> it is likely that Nitazoxanide functions in a similar manner, decreasing the maximal effect of glutamate on mGluR1, regardless of the mechanism of action of the mutations.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> As treatment with Nitazoxanide also results in inhibition of WT receptor activity, however, <italic>inÂ vivo</italic> drug titration will be required to assess therapeutic efficacy. Nonetheless, these results suggest a viable therapeutic strategy using mGlur1 inhibitors for individuals with gain-of-function mutations in <italic>GRM1.</italic></p>
      <p id="p0080">In summary, we report that dominant mutations in <italic>GRM1</italic> cause spinocerebellar ataxia type 44 (SCA44). Our study not only emphasizes the central role of mGluR1-mediated signaling in cerebellar function, but also provides valuable insights into genotype-phenotype correlations beyond ataxia. The finding that drugs modulate mGluR1-mediated signaling in the presence of human mutations warrants further exploration of possible therapeutic avenues involving mGluR1 pathways.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Curtis</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Phillis</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Chemical excitation of spinal neurones</article-title>
          <source>Nature</source>
          <volume>183</volume>
          <year>1959</year>
          <fpage>611</fpage>
          <lpage>612</lpage>
          <pub-id pub-id-type="pmid">13632811</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Meera</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pulst</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Otis</surname>
              <given-names>T.S.</given-names>
            </name>
          </person-group>
          <article-title>Cellular and circuit mechanisms underlying spinocerebellar ataxias</article-title>
          <source>J.Â Physiol.</source>
          <volume>594</volume>
          <year>2016</year>
          <fpage>4653</fpage>
          <lpage>4660</lpage>
          <pub-id pub-id-type="pmid">27198167</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Power</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>Empson</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Are Type 1 metabotropic glutamate receptors a viable therapeutic targetÂ for the treatment of cerebellar ataxia?</article-title>
          <source>J.Â Physiol.</source>
          <volume>594</volume>
          <year>2016</year>
          <fpage>4643</fpage>
          <lpage>4652</lpage>
          <pub-id pub-id-type="pmid">26748626</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Rossi</surname>
              <given-names>P.I.A.</given-names>
            </name>
            <name>
              <surname>Vaccari</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Terracciano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Doria-Lamba</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Facchinetti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Priolo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ayuso</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>De Jorge</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gimelli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Santorelli</surname>
              <given-names>F.M.</given-names>
            </name>
          </person-group>
          <article-title>The metabotropic glutamate receptor 1, GRM1: evaluation as a candidate gene for inherited forms of cerebellar ataxia</article-title>
          <source>J.Â Neurol.</source>
          <volume>257</volume>
          <year>2010</year>
          <fpage>598</fpage>
          <lpage>602</lpage>
          <pub-id pub-id-type="pmid">19924463</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Guergueltcheva</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Azmanov</surname>
              <given-names>D.N.</given-names>
            </name>
            <name>
              <surname>Angelicheva</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Chamova</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Florez</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bynevelt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cherninkova</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bojinova</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1</article-title>
          <source>Am. J. Hum. Genet.</source>
          <volume>91</volume>
          <year>2012</year>
          <fpage>553</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="pmid">22901947</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Davarniya</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kahrizi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Musante</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Fattahi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hosseini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Maqsoud</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Farajollahi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wienker</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Ropers</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Najmabadi</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The role of a novel TRMT1 gene mutation and rare GRM1 gene defect in intellectual disability in two Azeri families</article-title>
          <source>PLoS ONE</source>
          <volume>10</volume>
          <year>2015</year>
          <fpage>e0129631</fpage>
          <pub-id pub-id-type="pmid">26308914</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Parolin Schnekenberg</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>W.I.L.</given-names>
            </name>
            <name>
              <surname>DâAdamo</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Pessia</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fawcett</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Sims</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gillard</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hudspith</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>De novo point mutations in patients diagnosed with ataxic cerebral palsy</article-title>
          <source>Brain</source>
          <volume>138</volume>
          <year>2015</year>
          <fpage>1817</fpage>
          <lpage>1832</lpage>
          <pub-id pub-id-type="pmid">25981959</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Mencacci</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Rubio-Agusti</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Zdebik</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Asmus</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Ludtmann</surname>
              <given-names>M.H.R.</given-names>
            </name>
            <name>
              <surname>Ryten</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Plagnol</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Hauser</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Bandres-Ciga</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bettencourt</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia</article-title>
          <source>Am. J. Hum. Genet.</source>
          <volume>96</volume>
          <year>2015</year>
          <fpage>938</fpage>
          <lpage>947</lpage>
          <pub-id pub-id-type="pmid">25983243</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Hartmann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Henning</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Konnerth</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>mGluR1/TRPC3-mediated synaptic transmission and calcium signaling in mammalian central neurons</article-title>
          <source>Cold Spring Harb. Perspect. Biol.</source>
          <volume>3</volume>
          <year>2011</year>
          <fpage>1</fpage>
          <lpage>16</lpage>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Petralia</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Doan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Breder</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Ruggiero</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lanahan</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Wenthold</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Worley</surname>
              <given-names>P.F.</given-names>
            </name>
          </person-group>
          <article-title>Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins</article-title>
          <source>Neuron</source>
          <volume>21</volume>
          <year>1998</year>
          <fpage>707</fpage>
          <lpage>716</lpage>
          <pub-id pub-id-type="pmid">9808458</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Kammermeier</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Surface clustering of metabotropic glutamate receptor 1 induced by long Homer proteins</article-title>
          <source>BMC Neurosci.</source>
          <volume>7</volume>
          <year>2006</year>
          <fpage>1</fpage>
          <pub-id pub-id-type="pmid">16393337</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Bhattacharyya</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Inside story of group I metabotropic glutamate receptors (mGluRs)</article-title>
          <source>Int. J. Biochem. Cell Biol.</source>
          <volume>77</volume>
          <issue>PtÂ B</issue>
          <year>2016</year>
          <fpage>205</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">26987586</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Kammermeier</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Worley</surname>
              <given-names>P.F.</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Homer proteins regulate coupling of group I metabotropic glutamate receptors to N-type calcium and M-type potassium channels</article-title>
          <source>J.Â Neurosci.</source>
          <volume>20</volume>
          <year>2000</year>
          <fpage>7238</fpage>
          <lpage>7245</lpage>
          <pub-id pub-id-type="pmid">11007880</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Choe</surname>
              <given-names>E.S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J.Q.</given-names>
            </name>
          </person-group>
          <article-title>Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum</article-title>
          <source>Brain Res. Mol. Brain Res.</source>
          <volume>94</volume>
          <year>2001</year>
          <fpage>75</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">11597767</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Kroeze</surname>
              <given-names>W.K.</given-names>
            </name>
            <name>
              <surname>Sassano</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.-P.</given-names>
            </name>
            <name>
              <surname>Lansu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>McCorvy</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>GiguÃ¨re</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Sciaky</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>B.L.</given-names>
            </name>
          </person-group>
          <article-title>PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</article-title>
          <source>Nat. Struct. Mol. Biol.</source>
          <volume>22</volume>
          <year>2015</year>
          <fpage>362</fpage>
          <lpage>369</lpage>
          <pub-id pub-id-type="pmid">25895059</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gregory</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Niswender</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Katritch</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Meiler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cherezov</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator</article-title>
          <source>Science</source>
          <volume>344</volume>
          <year>2014</year>
          <fpage>58</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">24603153</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Lohse</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Maiellaro</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Calebiro</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Kinetics and mechanism of G protein-coupled receptor activation</article-title>
          <source>Curr. Opin. Cell Biol.</source>
          <volume>27</volume>
          <year>2014</year>
          <fpage>87</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">24530699</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Dzubay</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Otis</surname>
              <given-names>T.S.</given-names>
            </name>
          </person-group>
          <article-title>Climbing fiber activation of metabotropic glutamate receptors on cerebellar purkinje neurons</article-title>
          <source>Neuron</source>
          <volume>36</volume>
          <year>2002</year>
          <fpage>1159</fpage>
          <lpage>1167</lpage>
          <pub-id pub-id-type="pmid">12495629</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Batchelor</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Garthwaite</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Frequency detection and temporally dispersed synaptic signal association through aÂ metabotropic glutamate receptor pathway</article-title>
          <source>Nature</source>
          <volume>385</volume>
          <year>1997</year>
          <fpage>74</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">8985249</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>E.B.E.</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>P.L.</given-names>
            </name>
            <name>
              <surname>Glitsch</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>G.T.</given-names>
            </name>
            <name>
              <surname>Achilli</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Nolan</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>E.M.C.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>K.E.</given-names>
            </name>
          </person-group>
          <article-title>A point mutation in TRPC3 causes abnormal Purkinje cell development and cerebellar ataxia in moonwalker mice</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>106</volume>
          <year>2009</year>
          <fpage>6706</fpage>
          <lpage>6711</lpage>
          <pub-id pub-id-type="pmid">19351902</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Power</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Empson</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Prolonged type 1 metabotropic glutamate receptor dependent synaptic signaling contributes to spino-cerebellar ataxia type 1</article-title>
          <source>J.Â Neurosci.</source>
          <volume>36</volume>
          <year>2016</year>
          <fpage>4910</fpage>
          <lpage>4916</lpage>
          <pub-id pub-id-type="pmid">27147646</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal" id="sref22">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>T.-S.</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Herndon</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Huynh</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Pulst</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Bezprozvanny</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2</article-title>
          <source>J.Â Neurosci.</source>
          <volume>29</volume>
          <year>2009</year>
          <fpage>9148</fpage>
          <lpage>9162</lpage>
          <pub-id pub-id-type="pmid">19625506</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Maltecca</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Baseggio</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Consolato</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Mazza</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Podini</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>S.M.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Drago</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Bahr</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Puliti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Codazzi</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model</article-title>
          <source>J.Â Clin. Invest.</source>
          <volume>125</volume>
          <year>2015</year>
          <fpage>263</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="pmid">25485680</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>Fogel</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>E.B.E.</given-names>
            </name>
          </person-group>
          <article-title>Do mutations in the murine ataxia gene <italic>TRPC3</italic> cause cerebellar ataxia in humans?</article-title>
          <source>Mov. Disord.</source>
          <volume>30</volume>
          <year>2015</year>
          <fpage>284</fpage>
          <lpage>286</lpage>
          <pub-id pub-id-type="pmid">25477146</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Ohtani</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tabata</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kishimoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Fukaya</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kase</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kassai</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nakao</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>The synaptic targeting of mGluR1 by its carboxyl-terminal domain is crucial for cerebellar function</article-title>
          <source>J.Â Neurosci.</source>
          <volume>34</volume>
          <year>2014</year>
          <fpage>2702</fpage>
          <lpage>2712</lpage>
          <pub-id pub-id-type="pmid">24523559</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>Kniazeff</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>PrÃ©zeau</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rondard</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pin</surname>
              <given-names>J.-P.</given-names>
            </name>
            <name>
              <surname>Goudet</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Dimers and beyond: The functional puzzles of class C GPCRs</article-title>
          <source>Pharmacol. Ther.</source>
          <volume>130</volume>
          <year>2011</year>
          <fpage>9</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">21256155</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Ichise</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kano</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yanagihara</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Nakao</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Shigemoto</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Katsuki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Aiba</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination</article-title>
          <source>Science</source>
          <volume>288</volume>
          <year>2000</year>
          <fpage>1832</fpage>
          <lpage>1835</lpage>
          <pub-id pub-id-type="pmid">10846166</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Aiba</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kano</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Stanton</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Herrup</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zwingman</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Tonegawa</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice</article-title>
          <source>Cell</source>
          <volume>79</volume>
          <year>1994</year>
          <fpage>377</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="pmid">7954803</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>Rossi</surname>
              <given-names>P.I.A.</given-names>
            </name>
            <name>
              <surname>Musante</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Summa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pittaluga</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Emionite</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ikehata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rastaldi</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Ravazzolo</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Puliti</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Compensatory molecular and functional mechanisms in nervous system of the Grm1(crv4) mouse lacking the mGlu1 receptor: a model for motor coordination deficits</article-title>
          <source>Cereb. Cortex</source>
          <volume>23</volume>
          <year>2013</year>
          <fpage>2179</fpage>
          <lpage>2189</lpage>
          <pub-id pub-id-type="pmid">22791805</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>Brody</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Conquet</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Geyer</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Disruption of prepulse inhibition in mice lacking mGluR1</article-title>
          <source>Eur. J. Neurosci.</source>
          <volume>18</volume>
          <year>2003</year>
          <fpage>3361</fpage>
          <lpage>3366</lpage>
          <pub-id pub-id-type="pmid">14686909</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Conquet</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bashir</surname>
              <given-names>Z.I.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ferraguti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bordi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Franz-Bacon</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Reggiani</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Matarese</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>CondÃ©</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1</article-title>
          <source>Nature</source>
          <volume>372</volume>
          <year>1994</year>
          <fpage>237</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="pmid">7969468</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Lum</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Matosin</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.-F.</given-names>
            </name>
            <name>
              <surname>Ooi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Newell</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>Neurodevelopmental expression profile of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment</article-title>
          <source>Sci. Rep.</source>
          <volume>6</volume>
          <year>2016</year>
          <fpage>34391</fpage>
          <pub-id pub-id-type="pmid">27721389</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>Coutelier</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Burglen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mundwiller</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Abada-Bendib</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chantot-Bastaraud</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rougeot</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cournelle</surname>
              <given-names>M.-A.</given-names>
            </name>
            <name>
              <surname>Milh</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Toutain</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>GRID2 mutations span from congenital to mild adult-onset cerebellar ataxia</article-title>
          <source>Neurology</source>
          <volume>84</volume>
          <year>2015</year>
          <fpage>1751</fpage>
          <lpage>1759</lpage>
          <pub-id pub-id-type="pmid">25841024</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>Van Schil</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Meire</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Karlstetter</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bauwens</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Verdin</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Coppieters</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Scheiffert</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Van Nechel</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Langmann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Deconinck</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>De Baere</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Early-onset autosomal recessive cerebellar ataxia associated with retinal dystrophy: new human hotfoot phenotype caused by homozygous GRID2 deletion</article-title>
          <source>Genet. Med.</source>
          <volume>17</volume>
          <year>2015</year>
          <fpage>291</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">25122145</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>Maier</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Klopocki</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tzschach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>De novo partial deletion in GRID2 presenting with complicated spastic paraplegia</article-title>
          <source>Muscle Nerve</source>
          <volume>49</volume>
          <year>2014</year>
          <fpage>289</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="pmid">24122788</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Hills</surname>
              <given-names>L.B.</given-names>
            </name>
            <name>
              <surname>Masri</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Konno</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kakegawa</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>A.-T.N.</given-names>
            </name>
            <name>
              <surname>Lim-Melia</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Chandy</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Partlow</surname>
              <given-names>J.N.</given-names>
            </name>
            <name>
              <surname>Al-Saffar</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Deletions in GRID2 lead to a recessive syndrome of cerebellar ataxia and tonic upgaze in humans</article-title>
          <source>Neurology</source>
          <volume>81</volume>
          <year>2013</year>
          <fpage>1378</fpage>
          <lpage>1386</lpage>
          <pub-id pub-id-type="pmid">24078737</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal" id="sref37">
          <person-group person-group-type="author">
            <name>
              <surname>Utine</surname>
              <given-names>G.E.</given-names>
            </name>
            <name>
              <surname>HaliloÄlu</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Salanci</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Ãetinkaya</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kiper</surname>
              <given-names>P.O.</given-names>
            </name>
            <name>
              <surname>Alanay</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Aktas</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>BoduroÄlu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>AlikaÅifoÄlu</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A homozygous deletion in GRID2 causes a human phenotype with cerebellar ataxia and atrophy</article-title>
          <source>J.Â Child Neurol.</source>
          <volume>28</volume>
          <year>2013</year>
          <fpage>926</fpage>
          <lpage>932</lpage>
          <pub-id pub-id-type="pmid">23611888</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal" id="sref38">
          <person-group person-group-type="author">
            <name>
              <surname>Conti</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Aghaie</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cilli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Caridi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Musante</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Candiano</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Castagna</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fairen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ravazzolo</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>crv4, a mouse model for human ataxia associated with kyphoscoliosis caused by an mRNA splicing mutation of the metabotropic glutamate receptor 1 (Grm1)</article-title>
          <source>Int. J. Mol. Med.</source>
          <volume>18</volume>
          <year>2006</year>
          <fpage>593</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="pmid">16964410</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal" id="sref39">
          <person-group person-group-type="author">
            <name>
              <surname>Nicoletti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bruno</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Ngomba</surname>
              <given-names>R.T.</given-names>
            </name>
            <name>
              <surname>Gradini</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Battaglia</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Metabotropic glutamate receptors as drug targets: whatâs new?</article-title>
          <source>Curr. Opin. Pharmacol.</source>
          <volume>20</volume>
          <year>2015</year>
          <fpage>89</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">25506748</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal" id="sref40">
          <person-group person-group-type="author">
            <name>
              <surname>Ai</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Welsh</surname>
              <given-names>W.J.</given-names>
            </name>
          </person-group>
          <article-title>Identification of nitazoxanide as a group I metabotropic glutamate receptor negative modulator for the treatment of neuropathic pain: an inÂ silico drug repositioning study</article-title>
          <source>Pharm. Res.</source>
          <volume>32</volume>
          <year>2015</year>
          <fpage>2798</fpage>
          <lpage>2807</lpage>
          <pub-id pub-id-type="pmid">25762088</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal" id="sref41">
          <person-group person-group-type="author">
            <name>
              <surname>Carroll</surname>
              <given-names>F.Y.</given-names>
            </name>
            <name>
              <surname>Stolle</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beart</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Voerste</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brabet</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Mauler</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Joly</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Antonicek</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bockaert</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>MÃ¼ller</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity</article-title>
          <source>Mol. Pharmacol.</source>
          <volume>59</volume>
          <year>2001</year>
          <fpage>965</fpage>
          <lpage>973</lpage>
          <pub-id pub-id-type="pmid">11306677</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal" id="sref42">
          <person-group person-group-type="author">
            <name>
              <surname>Willard</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Koochekpour</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Glutamate, glutamate receptors, and downstream signaling pathways</article-title>
          <source>Int. J. Biol. Sci.</source>
          <volume>9</volume>
          <year>2013</year>
          <fpage>948</fpage>
          <lpage>959</lpage>
          <pub-id pub-id-type="pmid">24155668</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="app1">
      <title>Accession Numbers</title>
      <p id="p0090">The accession number for the spinocerebellar ataxia type 44 (SCA44) reported in this paper is MIM: <ext-link ext-link-type="omim" xlink:href="617635" id="intref0070">617635</ext-link>.</p>
    </sec>
    <sec id="app4">
      <title>Web Resources</title>
      <p id="p0105">
        <list list-type="simple">
          <list-item id="u0010">
            <p id="p0110">1000 Genomes, <ext-link ext-link-type="uri" xlink:href="http://www.internationalgenome.org/" id="intref0080">http://www.internationalgenome.org/</ext-link></p>
          </list-item>
          <list-item id="u0015">
            <p id="p0115">Allen Mouse Brain Atlas, <ext-link ext-link-type="uri" xlink:href="http://mouse.brain-map.org" id="intref0085">http://mouse.brain-map.org</ext-link></p>
          </list-item>
          <list-item id="u0020">
            <p id="p0120">Complete Genomics, <ext-link ext-link-type="uri" xlink:href="http://www.completegenomics.com" id="intref0090">http://www.completegenomics.com</ext-link></p>
          </list-item>
          <list-item id="u0025">
            <p id="p0125">ExAC Browser, <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/" id="intref0095">http://exac.broadinstitute.org/</ext-link></p>
          </list-item>
          <list-item id="u0030">
            <p id="p0130">HBT â Human Brain Transcriptome, <ext-link ext-link-type="uri" xlink:href="http://hbatlas.org/" id="intref0100">http://hbatlas.org/</ext-link></p>
          </list-item>
          <list-item id="u0035">
            <p id="p0135">NHLBI Exome Sequencing Project (ESP) Exome Variant Server, <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/" id="intref0105">http://evs.gs.washington.edu/EVS/</ext-link></p>
          </list-item>
          <list-item id="u0040">
            <p id="p0140">OMIM, <ext-link ext-link-type="uri" xlink:href="http://www.omim.org/" id="intref0110">http://www.omim.org/</ext-link></p>
          </list-item>
        </list>
      </p>
    </sec>
    <sec id="app3" sec-type="supplementary-material">
      <title>Supplemental Data</title>
      <p id="p0100">
        <supplementary-material content-type="local-data" id="mmc1">
          <caption>
            <title>Document S1. FigureÂ S1 and Supplemental Note</title>
          </caption>
          <media xlink:href="mmc1.pdf"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="mmc2">
          <caption>
            <title>Table S1. Horizontal Sequence Coverage of 92 Ataxia-Associated Genes</title>
          </caption>
          <media xlink:href="mmc2.xlsx"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="mmc3">
          <caption>
            <title>Document S2. Article plus Supplemental Data</title>
          </caption>
          <media xlink:href="mmc3.pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack id="ack0010">
      <title>Acknowledgments</title>
      <p>Supported by the European Union's Horizon 2020 research and innovation programme (under <funding-source id="gs1">the Marie SkÅodowska-Curie</funding-source> grant agreement number 699978) (this publication reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein) (L.M.W.), the <funding-source id="gs2">John Fell OUP Fund</funding-source> (A.H.N., E.B.E.B., L.M.W.), <funding-source id="gs3">Action Medical Research</funding-source>, the <funding-source id="gs4">Henry Smith Charity</funding-source> (A.H.N.), <funding-source id="gs5">CNPq (National Council for Scientific and Technological Development), Brazil</funding-source> (R.P.S.), the <funding-source id="gs6">Medical Research Council (UK) Computational Genomics Analysis and Training programme</funding-source> (G1000902) (K.F., D.S.), and the <funding-source id="gs7">Wellcome Trust in Equipment and Strategic Award (Synaptopathies) funding</funding-source> (WT093205MA and WT104033AIA) (C.B., H.H.). We thank Dr. Gilad Barnea for the kind gift of HTLA cells, Prof. Bryan Roth for the GRM1-Tango plasmid, Hannah Sleven for her contributions, and the affected individuals and their families for their support of this research.</p>
    </ack>
    <fn-group>
      <fn id="app2" fn-type="supplementary-material">
        <p id="p0095">Supplemental Data include one figure, one table, and Supplemental Note (containing case reports) and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.ajhg.2017.08.005" id="intref0075">http://dx.doi.org/10.1016/j.ajhg.2017.08.005</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>